Bio-Technopark
In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On the former site of the Schweizerische Wagons- und Aufzügefabrik AG and on neighboring sites, 90,000 m2 of laboratory, production and office space is now leased to over 50 companies and 30 academic institutions.
Leasing
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with communal infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
Services
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
News
SanaGen, InSphero and Sanquin Awarded with Eurostars Grant for a Breakthrough Gene Therapy, Poised to Become First “Cure” for Severe Alpha-1 anti-Trypsin (AAT) Deficiency (AATD)
Zürich, April 22, 2024 In a notable collaboration that underscores the power of innovation in drug discovery, SanaGen and InSphero, alongside the renowned Sanquin research institute, have been awarded a 1.3 million euro grant for the ambitious project NOCAAVAAT. The NOCAAVAAT project, which aims to develop a breakthrough gene therapy for severe Alpha-1 anti-Trypsin (AAT)...
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that all motions proposed by the Board of Directors at the Annual General meeting were...